News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gentium S.p.A. Receives Positive Opinion From European Medicines Agency's CHMP for Defitelio


7/26/2013 9:13:44 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VILLA GUARDIA, Italy, July 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, following its request for re-examination, the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") adopted a positive opinion for Defitelio recommending a Marketing Authorization Application ("MAA") under exceptional circumstances, for the treatment of severe hepatic veno-occlusive disease ("VOD") in adults and children undergoing hematopoietic stem cell transplantation therapy.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES